SCN1A and encephalopathy, progressive, early-onset, with brain edema and/or leukoencephalopathy: In phase 1/2a trials of zorevunersen (STK-001), an antisense oligonucleotide that increases expression of NaV1.1 channels [152], median convulsive seizure frequency was reduced at 3 and 6 months after the last dose compared with baseline in children with SCN1A-positive Dravet syndrome [153,154].